Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Non-Current Deferred Tax Liability (2017 - 2025)

Ultragenyx Pharmaceutical has reported Non-Current Deferred Tax Liability over the past 9 years, most recently at $30.0 million for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability changed 0.0% to $30.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $30.0 million for FY2025, 0.0% changed from the prior year.
  • Non-Current Deferred Tax Liability was $30.0 million for Q4 2025 at Ultragenyx Pharmaceutical, roughly flat from $30.1 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $33.3 million in Q1 2021 and troughed at $30.0 million in Q4 2024.
  • The 5-year median for Non-Current Deferred Tax Liability is $31.7 million (2022), against an average of $31.5 million.
  • Year-over-year, Non-Current Deferred Tax Liability changed 0.0% in 2021 and then dropped 5.08% in 2023.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $33.3 million in 2021, then fell by 4.92% to $31.7 million in 2022, then dropped by 5.08% to $30.1 million in 2023, then fell by 0.19% to $30.0 million in 2024, then changed by 0.0% to $30.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Non-Current Deferred Tax Liability are $30.0 million (Q4 2025), $30.1 million (Q3 2025), and $30.1 million (Q2 2025).